Vol 13: Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients.Report as inadecuate



 Vol 13: Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients.


Vol 13: Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients. - Download this document for free, or read online. Document in PDF available to download.

Download or read this book online for free in PDF: Vol 13: Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients.
This article is from BMC Infectious Diseases, volume 13.AbstractBackground: Cytomegalovirus CMV is the most common opportunistic infection following lung transplantation. CMV replication in the lung allograft is described as accelerating the development of bronchiolitis obliterans syndrome BOS. Finding a strategy to prevent CMV infection is an important issue. Methods: We performed a retrospective, single-centre study of 114 lung transplant recipients LTRs who underwent lung transplantation from January 2001 to December 2006. In a smaller cohort of 88 CMV seropositive R+ LTRs, three months of valganciclovir prophylaxis 2004-2006 was compared to three months of oral ganciclovir 2001-2003 with respect to the incidence of CMV infection-disease, the severity of CMV disease, acute rejection, BOS-free 4 year survival and 4 year survival. In the whole group of 114 LTRs the impact of CMV infection on long-term survival BOS free 4 year survival and 6 year survival was assessed. Results: For the cohort of 88 CMV seropositive LTRs, the incidence of CMV infection-disease at one year was lower in the valganciclovir group compared to the ganciclovir group 24% vs. 54%, p = 0.003. There was a tendency towards reduced CMV disease, from 33% to 20% and a significant lower incidence of asymptomatic CMV infection 22% vs. 4%, p = 0.005. A lower incidence of acute rejection was observed in the valganciclovir group. However, there was no significant difference between the two groups in BOS free 4 year survival and 4 year survival.For the entire group of 114 LTRs, BOS-free 4 year survival for recipients with CMV disease was 32%, p = 0.005 and among those with asymptomatic CMV infection 36%, p = 0.061 as compared with patients without CMV infection 69%. Six year survival was lower among patients with CMV disease, 64%, p = 0.042 and asymptomatic CMV infection 55%, p = 0.018 than patients without CMV infection 84%. Conclusions: A lower incidence of CMV infection-disease and acute rejections was observed with valganciclovir 3 months when compared to oral ganciclovir 3 months. The long-term impact of CMV infection-disease was significant for BOS-free survival and survival.



Author: Johansson, Inger; Martensson, Gunnar; Nystrom, Ulla; Nasic, Salmir; Andersson, Rune

Source: https://archive.org/







Related documents